Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial | Zendy

Jackie Bosch | Zendy; Eva Lonn | Zendy; Gilles R. Dagenais | Zendy; Peggy Gao | Zendy; Patricio LópezJaramillo | Zendy; Jun Zhu | Zendy; Prem Pais | Zendy; Álvaro Avezum | Zendy; Karen Sliwa | Zendy; И Е Чазова | Zendy; Ron J.G. Peters | Zendy; Claes Held | Zendy; Khalid Yusoff | Zendy; Basil S. Lewis | Zendy; William D. Toff | Zendy; Kamlesh Khunti | Zendy; Christopher M. Reid | Zendy; Lawrence A. Leiter | Zendy; Salim Yusuf | Zendy; Robert G. Hart | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial

Author(s) -

Jackie Bosch,

Eva Lonn,

Gilles R. Dagenais,

Peggy Gao,

Patricio LópezJaramillo,

Jun Zhu,

Prem Pais,

Álvaro Avezum,

Karen Sliwa,

И Е Чазова,

Ron J.G. Peters,

Claes Held,

Khalid Yusoff,

Basil S. Lewis,

William D. Toff,

Kamlesh Khunti,

Christopher M. Reid,

Lawrence A. Leiter,

Salim Yusuf,

Robert G. Hart

Publication year - 2021

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.120.030790

Subject(s) - medicine , stroke (engine) , rosuvastatin , hazard ratio , placebo , blood pressure , cardiology , confidence interval , mechanical engineering , alternative medicine , pathology , engineering

The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary analyses of stroke outcomes by stroke subtype, predictors, treatment effects in key subgroups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research